Miramontes Capital’s AbbVie ABBV Stock Holding History

Miramontes Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$923K	Buy	3,668 +104	+3%	+$22.4K	0.29%	54
2026 Q1	$775K	Sell	3,564 -67	-2%	-$14.9K	0.27%	57
2025 Q4	$830K	Buy	+3,631	New	+$827K	0.28%	54

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Miramontes Capital's ABBV Position: Q2 2026 in Review

Miramontes Capital increased its AbbVie (ABBV) stake by 2.9% in Q2 2026, buying an estimated $22.4K and bringing the position to 3,668 shares worth $923K. The position accounts for 0.29% of the portfolio, ranked #54.

Miramontes Capital first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,231 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Miramontes Capital held 3,668 shares of AbbVie worth $923K as of Q2 2026.
Miramontes Capital bought 104 AbbVie shares in Q2 2026, an estimated $22.4K.
AbbVie made up 0.29% of Miramontes Capital's portfolio in Q2 2026, its #54 holding.
Miramontes Capital first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,231 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Miramontes Capital's 13F filing for Q2 2026, filed 9 Sep 2026.